Trials / Completed
CompletedNCT00448630
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
A MULTI-CENTER, NON-INVASIVE OBSERVATIONAL STUDY OF METABOLIC SYNDROME PARAMETERS IN SCHIZOPHRENIC PATIENTS USING ATYPICAL ANTIPSYCHOTICS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 328 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
Detailed description
Sampling Method Details: Group of patients using the same atypical anti-psychotic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Non-interventional study |
Timeline
- Start date
- 2007-10-23
- Primary completion
- 2008-07-30
- Completion
- 2008-07-30
- First posted
- 2007-03-19
- Last updated
- 2022-05-03
- Results posted
- 2010-07-07
Locations
47 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00448630. Inclusion in this directory is not an endorsement.